🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — April 16, 2026

Across the 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily financials, insurers, and related blue-chips, with some small-caps), Q1 2026 earnings dominate, revealing strong YoY net income growth averaging +100% in key financials (Travelers +333%, BNY +42% EPS, US Bancorp +13.8%, BancFirst +12.3%, Bank First +9.9%) driven by lower catastrophe losses, NII expansion (Bank First +45.8% YoY), and fee growth, though QoQ dips (-4.9% NI US Bancorp), premium declines (Travelers -2% NWP), and NIM compression (Bank First -1.2% QoQ) signal moderating momentum. Capital allocation remains shareholder-friendly with dividend increases (Travelers +14% to $1.25, Bank First +22.2% YoY to $0.55) and buybacks ($2.223B Travelers Q1, $1.8B 10-Q). Small-caps show distress patterns: revenue drops (Hooker -20.5% Q4, Vipshop -2.3% FY), net losses, dilution risks (RenovoRx 16M shares), auditor changes (LanzaTech), and filing delays (CETI, AMC). Biotech highlights include MeiraGTx positive 3-yr clinical data (17-pt XQ improvement) and J&J asset buy ($25M upfront). Over 15 proxy filings cluster AGMs in May-Jun 2026 as near-term catalysts, with neutral sentiment but positive exec comp approvals. Portfolio-level: Financials outperform (ROE 19.7% Travelers), but watch margin trends and small-cap liquidity; actionable buy dips in strong capital returners.

26 high priority 24 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 16, 2026

Across 50 SEC filings for April 16, 2026, mixed sentiments dominate with 18 mixed, 6 positive, 5 negative, and others neutral, reflecting resilient revenue growth in semiconductors (TSMC +31.6% YoY) and consumer giants (PepsiCo +8.5% YoY) offset by widening losses in small caps (e.g., Capstone net loss +728%, Ionetix -32%). Period-over-period trends show 12/20 annual reports with revenue growth averaging +45% YoY in outperformers like NextNRG (+195%) but declines in 8/20 (avg -20% YoY), margin expansions in TSMC (+ to 59.9%) contrasting compressions elsewhere. Capital allocation leans shareholder-friendly with buybacks (Hooker $5M, News Corp $1B program), dividend hikes (PepsiCo +4%, 54th year), and M&A/divestitures (CareDx $170M sale, First Financial acquisitions). Proxy season ramps up with 10+ AGMs in May-June 2026, signaling governance focus amid strong bank performance. Debt raises (Brookfield $1B notes, Herbalife $800M) indicate liquidity bolstering, but going concern doubts in 5 small caps highlight microcap risks. Portfolio implication: Favor large-cap growth (tech/consumer) over volatile small caps; monitor Q1 earnings catalysts.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 16, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent financials/REITs), proxy statements dominate (20+ DEF/DEFA14A) signaling annual meeting season with positive comp trends in Yum China (STI 216% payout) and Life360 (32% revenue growth), while Q1 2026 earnings reveal mixed financial performance: banks like Citizens Financial (+39% YoY NI), BancFirst (+12.3%), and Bank First (+9.9%) show robust NII growth (avg +22% YoY) post-acquisitions but NIM compression (-24 bps to -120 bps QoQ); consumer names like Hooker Furnishings report sales declines (-20.5% Q4 YoY) and impairments ($15.6M). Key trends include revenue acceleration in high-performers (TSMC +31.6% YoY, Life360 +32%) vs declines (Hooker FY -12.4%, N2OFF op loss +29%), dividend hikes (Bank First +22.2% YoY, Four Corners +3.2%), and capital raises/debt refinancings (TeraWulf $1.03B equity, Herbalife $800M notes). Critical developments: guidance cuts (Knight-Swift Q1 EPS slashed 70%), Nasdaq risks (Fathom, Smith Micro), and liquidations (NLOP portfolio down to 18 properties); implications favor financials for stability, caution retail amid weather/M&A costs, with catalysts in May/June meetings.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 16, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with broader financial crossovers), dominant themes include robust YoY Q1 2026 earnings growth in banks (avg +30% net income across Citizens, KeyCorp, BNY) contrasting QoQ softness (-2-3% revenue), a biotech funding surge (Achieve $354M, Revolution $1.65B equity +$500M notes, Alamar revenue +195% YoY), and 20+ 13F-HR filings revealing institutional portfolios overloaded with S&P 500 ETFs (e.g., iShares/Vanguard dominating 50-80% allocations) and megacap tech (Apple/NVIDIA top holdings). Healthcare-specific trends show Abbott's comparable sales +3.7% YoY but Nutrition decline -7.7% and Diagnostics weakness, offset by Exact Sciences M&A; operational metrics like Alamar's gross profit +385% YoY highlight proteomics growth outliers. Capital allocation leans shareholder-friendly with bank dividends steady ($0.46 Citizens, $0.17 South Plains) and buybacks (KeyCorp $389M, News Corp $1B program), while forward-looking catalysts cluster in May-Jun (earnings, AGMs, PDUFA). Portfolio-level patterns flag financial resilience amid rate pressures (NIM +24bps Citizens), biotech conviction via raises/appointments (Prime Medicine new CFO, Achieve new CEO), but risks in zero-revenue entities (Catalyst Crew) and cash flow swings (Grupo Galicia). Overall, actionable tilt to biotech catalysts and bank dividend stability, with 13Fs signaling passive rotation into broad indices.

12 high priority 38 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 16, 2026

Across 50 DEF 14A proxy statements filed primarily on April 16, 2026, for 2026 annual meetings (mostly May-June), companies emphasize 2025 performance to support advisory 'say-on-pay' votes, with 15+ filings highlighting YoY revenue growth averaging 25-35% in tech/biotech (e.g., Roblox +36%, Axon +33%, Life360 +32%) and steady FFO/AFFO gains in REITs (Four Corners FFO +$0.03 YoY). Financials dominate (20+ banks/BDCs) with branch optimizations, mergers (Mechanics Bancorp 91.7% owned post-merger), and capital returns (First Interstate $311.9M or 103% of NI via divs/buybacks). Positive sentiment in 12 filings tied to OP growth (Yum China +11%), backlog builds (Valaris $2.6B), and advisor upgrades (Stellus/Ridgepost $43B AUM); mixed/neutral in most due to dilution risks from equity plan expansions (e.g., Cohen +80% shares). Portfolio trends show margin expansion in high-performers (Life360 EBITDA margin +700bps to 19%) vs compression in others (Docusign GAAP EPS -71%), signaling sector rotation to growth tech/healthcare amid financial stability. Key implications: High exec equity alignment boosts conviction, but 25+ seek share increases signaling dilution (avg +20-100%); monitor mid-2026 advisor closings and June liquidations for catalysts.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 16, 2026

The IPO Pipeline stream features 5 new S-1 filings (OLB Group, Disciplined Growth Acquisition, VisionWave Holdings, EagleRock Land, Luvulis Corp) and 1 S-4 (Qwest Corp), highlighting a surge in microcap IPOs/SPACs amid high-risk profiles and one telecom debt restructuring. EagleRock Land stands out with explosive YoY growth: revenues +308% to $72.2M, Adjusted EBITDA +383% to $35.5M, and acreage +59% to 193,875, though net losses widened from $1.1M to $73.1M due to expansion costs. Common themes include neutral-to-negative sentiments (1 neutral, 4 mixed, 1 negative), heavy risk disclosures (going concern doubts, dilution, low liquidity), no dividends across all, and limited forward-looking guidance beyond deal timelines. Qwest's $5.75B asset sale enabled $4.8B deleveraging but higher-cost refinancing signals mixed capital allocation. Portfolio-level trends show 1/6 with hyper-growth (energy services outlier), while 5/6 are pre-revenue or resale-focused with penny stock volatility. Market implications favor monitoring EagleRock for Permian water infrastructure catalysts but caution on dilution-heavy resales and SPAC redemption risks.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — April 16, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, proxy statements dominate (e.g., Arbor Realty, Excelerate Energy, Immunocore, Smith Micro, multiple bancorps) signaling peak 2026 AGM season with director elections, equity plans, and say-on-pay votes clustered in May-June. Financial trends show robust revenue growth in large caps like TSMC (+31.6% YoY to NT$3.8T, margins to 59.9%), PepsiCo (+8.6% YoY Q1 to $19.4B, OP +24.4%), Bilibili (+13.1% YoY to RMB30.3B with profit swing), but microcaps exhibit persistent losses narrowing (e.g., SEATech -75% YoY, Catalyst Crew -95% op ex) amid zero revenue and going concern doubts (Horizon Quantum, Ionetix, Data443). M&A/divestitures active: ESCO acquiring Megger ($1.5B financing), CareDx divesting Lab Products ($170M cash), Qwest debt exchange to simplify structure post-$5.75B asset sale. Indian filings highlight distress (AYM Syntex amalgamations, Future Consumer insolvency hearing, open offers at premiums). Capital allocation leans to deleveraging (Lumen/Qwest repaid $4.8B debt) and liquidity boosts (Lincoln Ed $125M facility). Portfolio-level: 12/25 with PoP data show avg revenue +15% YoY but mixed profitability; sector outliers in semis/consumer bullish, small caps bearish. Implications: Near-term catalysts from May meetings could drive volatility; favor large-cap growth over microcap risks.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 16, 2026

Across 32 filings primarily covering FY2025 10-Ks and Q1 2026 10-Qs, sentiment is overwhelmingly mixed (25/32), with microcap/development-stage firms (e.g., SEATech, JOCOM, Catalyst Crew) showing narrowed losses via expense cuts (avg ~70% improvement in 8 cases) but persistent zero revenue and going concern risks, while larger caps like PepsiCo (+8.6% revenue YoY), Fastenal (+12.4%), and Travelers (+333% net income) drove positive trends. Portfolio-level, revenue grew in 12/32 (avg +20% YoY where positive), but declined in 14 (avg -40%), with gross margins compressing in 10/32 (avg -200bps, e.g., Lakeland -820bps). Acquisitions/share issuances boosted assets in 15 firms (avg +100% YoY), but cash burn persists in 20+, offset by financing. Capital allocation leans toward buybacks/dividends in stables (Travelers $1.8B buyback, Fastenal dividend +12%), signaling conviction, while microcaps dilute via issuances. Key implication: Opportunities in turnaround microcaps narrowing losses and established consumer/insurance names, but watch margin pressures and working capital deficits amid 2026 economic uncertainty.

32 high priority 32 total filings
· daily

US SEC Trading Suspension Halt Orders — April 16, 2026

The single filing in the USA Trading Suspensions stream highlights a critical Nasdaq compliance deficiency for Fathom Holdings Inc. (FTHM), with its bid price below $1.00 for 30 consecutive business days as of April 10, 2026, violating Listing Rule 5550(a)(2). No period-over-period financial trends, insider activity, capital allocation, or forward-looking guidance beyond compliance are detailed in the enriched data, limiting quantitative comparisons across companies. The negative sentiment (9/10 materiality) signals heightened delisting risk, with 180 days until October 7, 2026, to regain a $1.00+ bid for 10 consecutive days under Rule 5810(c)(3)(A). Failure could trigger delisting, though a second 180-day period is possible if other Capital Market standards are met. This isolated event underscores small-cap vulnerability to regulatory halts amid potential sector weakness, with no immediate listing impact but evaluating options like reverse stock split. Portfolio implications point to monitoring similar bid-price deficient names for cascading suspension risks.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 16, 2026

Across 37 filings in the USA Corporate Distress & Bankruptcy stream, acute distress signals are limited to covenant breaches (Katapult's 10th waiver) and Nasdaq delisting risks (Fathom), but the dominant theme is aggressive liquidity accumulation via $5B+ in combined equity/debt raises, facility expansions, and refinancings, suggesting pre-emptive balance sheet fortifications amid potential sector headwinds. Standout period growth includes CareDx's Q1 revenue +39% YoY to $118M (Testing Services +48% YoY), Lincoln Educational's student starts +19-20% Q1 2026, contrasting Katapult's origination/charge-off defaults. Biotech leads capital inflows (Spyre $463M, Achieve $354M, TeraWulf $1.036B), while ABS issuances (GM $1.27B, Toyota $1.9B, BMW $1.5B) remain stable. No insider trading or dividend/buyback activity reported; forward-looking catalysts cluster in late April-May closings and Q3 divestitures. Portfolio-level implications: Microcap distress outliers amid broader turnaround maneuvers, with dilution risks from equity raises but enhanced liquidity for 20+ companies signaling resilience over collapse.

37 high priority 37 total filings
· daily

US Executive Officer Management Changes SEC — April 16, 2026

Across 39 filings on USA Executive & Director Changes from April 16, 2026, the dominant theme is a high volume of C-suite and board transitions, with 18 new CEO/CFO appointments or promotions (e.g., Eton Pharma, First Business, AMERISAFE, TON Strategy, Lifevantage, Prime Medicine) and 22 resignations/retirements (e.g., Sensei Bio conditional board overhaul, Rivulet CEO, Zscaler EVP), signaling planned successions amid growth phases but no widespread distress. Positive sentiment prevails in 11 cases (28%), particularly pharma/biotech hires with pedigrees from AstraZeneca/Novartis (Aktis), Nature’s Sunshine revenue +45% (Lifevantage), driven by experienced leaders; neutral in 25 (64%), mixed in 3. No explicit YoY/QoQ revenue declines noted, but forward-looking comp packages show aggressive incentives: avg new CEO base ~$650k, bonuses 40-60%, equity 1-2% shares, RSUs up to $215k vesting 5yrs. Capital allocation tilts to equity incentives over dividends/buybacks, with 8 firms issuing PSUs/RSUs/MIPs tied to EPS CAGR/TSR through 2030. Sector patterns emerge in financials (smooth annual meetings, equity plans approved) and pharma (high materiality 7-9/10 transitions). Implications: opportunities in growth-oriented small caps post-transition, risks from conditional changes (Sensei) and restructurings (MiMedx $40M savings but $4M charge).

39 high priority 39 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 16, 2026

Across 39 filings on USA Board Room Changes from April 16, 2026, a dominant theme is C-suite transitions, with 12 CFO appointments/promotions (e.g., Eton, Amerisafe, Prime Medicine) and 7 CEO changes (e.g., First Business, LifeVantage), signaling proactive succession planning amid growth phases in biotech/pharma (8/39 positive sentiment) and financials. Board refreshments are prevalent, with 15 new director appointments (e.g., Myomo, Aktis Oncology) featuring executives with proven revenue growth track records (e.g., LifeVantage CEO +45% revenue), while 14 resignations/step-downs (e.g., Zscaler EVP, Greenidge directors) cite personal reasons/no disagreements, suggesting orderly handovers. No broad YoY revenue declines noted, but mixed signals in financials like WesBanco's narrow 45.7M vs 25M say-on-pay vote (high opposition) contrast positive equity plan approvals (e.g., Farmers National 1M shares reserved). Sentiment skews positive/neutral (34/39), with biotech hires boosting operational metrics like pipeline advancement (Aktis, Xilio); capital allocation favors equity incentives (e.g., Quanta PSUs up to 600% payout by 2030). Implications: Bullish for small-cap biotechs with experienced leadership upgrades, watch financials for comp scrutiny; portfolio trend of internal promotions (4/12 CFOs) indicates stability vs external hires signaling transformation.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — April 16, 2026

Across four US SEC filings in the M&A & Takeover stream, themes center on SPAC lifecycle extensions and separations (2/4 filings), a biotech asset acquisition with mixed Phase 3 data, and a radioisotope producer's financing amid deepening losses. Period-over-period trends show stark contrasts: Ionetix revenue surged 67.7% YoY to $6.0M for FY2025 but net loss widened 32.0% YoY to $39.7M, cash plummeted 94.6% to $0.3M, and assets fell 11.6% to $35.0M; MeiraGTx's acquisition highlights strong secondary endpoints (e.g., p=0.006 LLQ PRO mobility) despite primary endpoint miss. SPACs Compass and SUMA extended timelines to July 2026 and enabled unit separations from April 20, 2026, signaling prolonged target hunts in tech-enabled sectors. Mixed/neutral sentiments dominate (3/4), with high materiality in Ionetix (going concern doubts) and MeiraGTx ($25M J&J deal for 2027 launch). Portfolio-level patterns indicate resilient M&A pursuit amid liquidity pressures, with biotech outliers in asset deals and SPACs comprising 50% of activity, implying near-term catalysts in business combinations.

4 high priority 4 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 16, 2026

Across 50 overnight SEC filings from April 15-16, 2026, overarching themes include robust revenue growth in select large-cap tech/semiconductor names like TSMC (+31.6% YoY to NT$3.8T) and Bilibili (+13.1% YoY with profit turnaround), contrasted by persistent losses and margin pressures in small-cap industrials and tech (e.g., Capstone op loss widened to $11M, Ionetix net loss +32% to $39.7M). Portfolio-level trends show 12/20 10-K/A filings with revenue growth averaging +40% YoY (outliers: NextNRG +195%, China Foods +40.5%), but net losses narrowing in only 7/15 cases amid cost cuts; gross margins improved in 6/12 (avg +150bps, led by TSMC + to 59.9%). Critical developments feature CareDx's $170M Lab divestiture (close Q3 2026), PepsiCo's affirmed FY26 guidance (organic rev 2-4%, EPS +4-6%) and +4% dividend, and multiple proxy votes for buybacks/equity plans. Sector patterns highlight financials' routine proxies (positive undertones in First Financial M&A), energy/utilities mixed (NextNRG rev surge vs Energy Co net income -4%), and small-cap going concern risks (5 flags). Market implications: Favor large-cap outperformers for growth; caution on microcaps with liquidity crunches; watch May-June AGMs for capital allocation votes.

27 high priority 23 medium 50 total filings
· daily

DHS Homeland Security Contracts — April 15, 2026

DHS represents the sole agency in this $329,952,976 obligation period, fully civilian with 0/1 defense-related contracts and a neutral average signal strength of 4.0/10. General Dynamics Information Technology, Inc. (General Dynamics Corp subsidiary) secured the highest-materiality award, a $329,952,976 cost-plus-fixed-fee delivery order from U.S. Citizenship and Immigration Services (USCIS) for IT sustainment services under full and open competition. The contract's performance ended in 2015-09-25 with $0 outlayed to date despite 20 subawards worth $156,598,839, indicating dormant historical backlog in DHS IT facilities management (NAICS 541513). Highest-conviction signal is neutral due to expired term and lack of spending activity. Key watch item is total outlayed amount and any post-2015 modifications or extensions.

1 total filings
· daily

New Federal Contractors — April 15, 2026

$3,349,025,927 in total obligations across 9 new federal contracts from April 15-15, 2026, are entirely civilian (0/9 defense-related), dominated by long-term IT, consulting, and support services awards to small businesses and subsidiaries from agencies including State ($2.31B), DOE ($294M combined), DHS ($330M), HHS ($88M), and Treasury ($128M). Highest-conviction bullish signal is XATOR LLC's $2.31B Department of State award, providing massive revenue visibility despite limited details. Neutral signals from historical contracts like General Dynamics IT's $330M DHS deal (with $0 outlayed post-2015) temper enthusiasm. Key risk is uneven outlay progress, with several contracts showing partial spending (e.g., 47-82% outlayed) and reliance on unexercised options.

9 total filings
· daily

Significant Contract Modifications ($10M+) — April 15, 2026

These 10 significant contract modifications total $3,349,099,541 in obligations, with 0/10 defense-related—all civilian agencies including State, DHS, DOE, HHS, Treasury, NASA, USAID, PBGC, and Commerce. Dominant themes are long-duration IT, professional services, and specialized equipment contracts, heavily weighted toward small businesses via set-asides or open competition. Highest-conviction bullish signal is XATOR LLC's $2,309,491,422 Department of State award (materiality 8/10), providing massive revenue potential despite sparse details. UNWIN CO's $213,772,540 DOE set-aside and SOFTRAMS LLC's $88,157,680 HHS delivery order further highlight small-business growth in security and healthcare IT. Key risk: stalled outlays on historical contracts like General Dynamics Information Technology's $329,952,976 DHS award (ended 2015, $0 outlayed). Watch option exercises and remaining obligations across long-term deals through 2032.

10 total filings
· daily

Contract Deobligations Alert — April 15, 2026

This Contract Deobligations Alert synthesizes $3,349,099,541 in total obligations across 10 civilian agency contracts from April 15, 2026, with 0/10 defense-related and average signal strength of 5.3/10. Dominant themes include long-duration IT, professional services, and specialized equipment awards to agencies like Department of State (69% of total via XATOR LLC's $2.31B), DOE ($214M UNWIN + $80M Bluewater), and HHS ($88M SOFTRAMS). Highest-conviction bullish signal is XATOR LLC's $2.31B Department of State award, providing massive revenue visibility despite unknown revenue/pricing details. Balanced signals show 7 bullish amid 3 neutrals, with no bearish. Key risk/watch item: stalled outlays on historical contracts like General Dynamics IT's $330M DHS award (ended 2015, $0 outlayed) and Lockheed Martin's $73,614 Commerce purchase ($0 outlayed), signaling potential deobligation exposure.

10 total filings
· daily

Contract Option Exercises — April 15, 2026

This digest covers $3,349,099,541 in contract option exercises across 10 awards from April 15-15, 2026, all from civilian agencies with zero defense-related activity. The portfolio is dominated by Department of State's $2.31B award to XATOR LLC, representing 69% of total value and the highest-conviction bullish signal for long-term revenue in security services. Other notable themes include DOE's sustained IT and security support to UNWIN CO ($213.8M) and Bluewater Federal Solutions ($80M, Tetra Tech subsidiary), alongside HHS/CMS IT to SOFTRAMS LLC ($88.2M). Key risk is uneven outlay execution, with GDIT's $330M DHS contract at $0 outlayed post-2015 performance end and several relying on unexercised options. Investors should monitor outlay progress and option exercises for revenue realization in civilian IT/services exposure.

10 total filings
· daily

Federal Professional Services Contracts — April 15, 2026

Two DOE professional services contracts totaling $293,785,850 in obligations highlight sustained civilian agency spending on security studies and IT support, with 0/2 defense-related awards. UNWIN CO's $213.8M small business set-aside contract (materiality 8/10) leads as the highest-conviction bullish signal, featuring $178.6M already outlayed and revenue visibility through April 2026. Bluewater Federal Solutions, Inc. (Tetra Tech, Inc. subsidiary) adds $80M obligated (potential $96.9M ceiling) in IT services, with $62.8M outlayed through September 2026. Dominant theme is DOE Headquarters Procurement Services prioritizing long-duration time-and-materials awards to small businesses. Key watch item: outlay progress on remaining balances amid 2026 contract end dates.

2 total filings